Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response
Caitlin Murphy, Andrea Muscat, David Ashley, Violet Mukaro, Linda West, Yang Liao, David Chisanga, Wei Shi, Ian Collins, Sally Baron-Hay, Sujata Patil, Geoffrey Lindeman, Mustafa Khasraw
PloS one | PUBLIC LIBRARY SCIENCE | Published : 2019
Awarded by National Medical Health and Research Council of Australia Centre of Research Excellence Grant
This study was funded by an unrestricted research grant from Specialised Therapeutics Australia, a National Medical Health and Research Council of Australia Centre of Research Excellence Grant (#1040978) and a Tuck Family Scholarship. Lake Imaging, Geelong, VIC, Australia provided support in the form of a salary for author LW. These funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.We would like to thank Christoffer Flensburg and Christophe Lefevre for their help in clonality analysis. WS is supported by a Walter and Eliza Hall Institute Centenary Fellowship sponsored by CSL.